{"id":"nxy-059","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Hypertension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NXY-059 works by neutralizing reactive oxygen species and free radicals that are generated during cerebral ischemia and reperfusion, thereby reducing oxidative stress-induced neuronal injury. This neuroprotective approach aims to limit the expansion of the infarct core and improve neurological outcomes when administered acutely after stroke onset.","oneSentence":"NXY-059 is a free radical-trapping agent that scavenges harmful free radicals produced during ischemic stroke to reduce neuronal damage.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:45.952Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute ischemic stroke (within 6 hours of symptom onset)"}]},"trialDetails":[{"nctId":"NCT04388475","phase":"PHASE2","title":"Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Oblato, Inc.","startDate":"2020-06-12","conditions":"Recurrent Malignant Glioma, Brain Glioblastoma","enrollment":57},{"nctId":"NCT02259595","phase":"PHASE1","title":"Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC","status":"COMPLETED","sponsor":"Otologic Pharmaceutics, Inc.","startDate":"2014-10","conditions":"Hearing Loss, Sensorineural Hearing Loss, Noise-Induced Hearing Loss","enrollment":32},{"nctId":"NCT00075959","phase":"PHASE2","title":"Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-08","conditions":"Intracerebral Hemorrhage","enrollment":600},{"nctId":"NCT00119626","phase":"PHASE3","title":"Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-06","conditions":"Cerebral Stroke, Ischemic Attack, Transient","enrollment":1700},{"nctId":"NCT00061022","phase":"PHASE3","title":"Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-05","conditions":"Cerebral Stroke, Stroke, Acute, Cerebrovascular Stroke","enrollment":3200}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ABDOMINAL DISTENSION"},{"count":1,"reaction":"ANAEMIA"},{"count":1,"reaction":"ANKLE FRACTURE"},{"count":1,"reaction":"ATRIAL FIBRILLATION"},{"count":1,"reaction":"ATRIOVENTRICULAR BLOCK COMPLETE"},{"count":1,"reaction":"ATRIOVENTRICULAR BLOCK FIRST DEGREE"},{"count":1,"reaction":"ATRIOVENTRICULAR BLOCK SECOND DEGREE"},{"count":1,"reaction":"ATROPHY"},{"count":1,"reaction":"BLOOD CREATININE INCREASED"},{"count":1,"reaction":"BLOOD UREA INCREASED"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NXY-059","genericName":"NXY-059","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NXY-059 is a free radical-trapping agent that scavenges harmful free radicals produced during ischemic stroke to reduce neuronal damage. Used for Acute ischemic stroke (within 6 hours of symptom onset).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}